While a recent study of BI6727 (Volesertib) demonstrated disappointing results in a phase three trial of adult AML patients we suggest that BI 6727 and other PLK1 inhibitors are excellent candidates for treatment of ATRT and should undergo further clinical investigation in children. This evidence concerns the gene PLK1 and acute myeloid leukemia.